Natera (NASDAQ:NTRA) posted its earnings results on Thursday. The medical research company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03), Briefing.com reports. Natera had a negative net margin of 59.07% and a negative return on equity of 752.93%. The firm had revenue of $65.30 million during the quarter, compared to the consensus estimate of $66.42 million. During the same quarter last year, the firm posted ($0.51) EPS. The business’s revenue was up 16.8% on a year-over-year basis. Natera updated its FY 2018 guidance to EPS.
Shares of NASDAQ:NTRA traded down $3.83 during trading on Friday, reaching $16.80. The stock had a trading volume of 4,391,474 shares, compared to its average volume of 457,138. Natera has a 52 week low of $8.60 and a 52 week high of $29.62. The stock has a market capitalization of $1.30 billion, a P/E ratio of -7.00 and a beta of 2.11.
In related news, COO Steven Leonard Chapman sold 45,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 11th. The shares were sold at an average price of $25.16, for a total value of $1,132,200.00. Following the completion of the transaction, the chief operating officer now owns 16,628 shares in the company, valued at approximately $418,360.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Burkes Brophy sold 108,108 shares of the business’s stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $24.31, for a total transaction of $2,628,105.48. Following the completion of the transaction, the chief financial officer now owns 22,000 shares of the company’s stock, valued at approximately $534,820. The disclosure for this sale can be found here. Insiders sold 2,014,988 shares of company stock valued at $48,674,710 in the last quarter. 13.18% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the stock. A.R.T. Advisors LLC bought a new position in Natera in the 1st quarter worth approximately $164,000. State Board of Administration of Florida Retirement System bought a new position in Natera in the 2nd quarter worth approximately $200,000. Meeder Asset Management Inc. raised its position in Natera by 920.5% in the 3rd quarter. Meeder Asset Management Inc. now owns 8,399 shares of the medical research company’s stock worth $200,000 after purchasing an additional 7,576 shares during the last quarter. Paradigm Capital Management Inc. NY bought a new position in Natera in the 2nd quarter worth approximately $207,000. Finally, Cubist Systematic Strategies LLC bought a new position in Natera in the 2nd quarter worth approximately $252,000. Hedge funds and other institutional investors own 67.46% of the company’s stock.
NTRA has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of Natera from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a research note on Tuesday, July 17th. BidaskClub upgraded shares of Natera from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 17th. Piper Jaffray Companies lifted their target price on shares of Natera to $27.00 and gave the company an “overweight” rating in a research note on Thursday, August 9th. Craig Hallum lifted their target price on shares of Natera from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, TheStreet upgraded shares of Natera from a “d” rating to a “c-” rating in a research note on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $28.25.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Recommended Story: Google Finance
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.